Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E. Kay, Tait D. Shanafelt, Kari G. Chaffee, Richard R. Furman, Peter Hillmen, Jeff Sharman, John F. Seymour, Asher A. Chanan-Khan, John C. Byrd, Jeffrey A. Jones, Lucille A. Ferrante, Lyndah K. Dreiling, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Angela J. Howes, Danelle James, Pankaj Bhargava, Andrew D. Zelenetz
Institutions: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Gilead Sciences (United States), Genentech, Mayo Clinic, Stanford Medicine, Stanford University, Weill Cornell Medicine, St James's University Hospital, Willamette Valley Cancer Institute and Research Center, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Mayo Clinic in Florida, The Ohio State University, Pharmacyclics (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2909749308